The 2026 probiotic and secretome paper reports no trial results because it is a trial protocol, not a results report. BMJ Open published it on 4 June 2026 while recruitment and data collection were planned for June 2025 to June 2026. Topical secretome means cell-free bioactive molecules released by mesenchymal stromal cells.
BMJ Open describes it as an investigational therapy for inflammatory skin conditions including acne. For people with acne-prone skin, that timing matters for shopping decisions. Products that combine probiotics and secretome cannot point to this trial protocol as proof they work. Lesion-count, severity, and microbiome outcomes are still to come.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What will the trial test?
- What did earlier probiotic studies show?
- When does an acne claim make a cream a drug?
- How should you read probiotic-secretome ads now?
What will the trial test?
The protocol plans a phase 2 double-blind randomized trial with four parallel arms. Each arm adds oral probiotics, topical secretome, both, or matching placebos to standard acne therapy. This design isolates the added effect of each experimental piece.
The registry entry focuses on adults with moderate-severe acne vulgaris. Participants receive standard skincare plus HEXBIO oral probiotic and topical secretome, or placebos. The goal is to test clinical and microbiome improvement together.
What did earlier probiotic studies show?
Earlier probiotic-acne evidence is strain-specific and mixed. Results for one strain or formula do not transfer automatically to another product.
Dose, strain, duration, and acne type all shape the outcome. A 2026 scoping review in MDPI Cosmetics pooled five Lactobacillus randomized trials with 332 patients. That pooled Lactobacillus analysis found no significant reduction in inflammatory, noninflammatory, or total lesions versus placebo or benzoyl peroxide.
When does an acne claim make a cream a drug?
The answer depends on what the label promises. The FDA says a cosmetic that claims to mitigate acne or another disease is classified as a drug. Cosmetics may only claim cleansing, beautifying, or appearance effects.
That distinction appears in the FDA reminder on cosmetic claims. A drug claim triggers drug review and approval before marketing. An appearance claim does not prove acne treatment.
How should you read probiotic-secretome ads now?
Health-benefit advertising needs human proof. The FTC requires competent and reliable scientific evidence, generally randomized controlled human testing.
The FTC health-products guidance says animal and laboratory studies alone do not prove human benefit. Until this trial publishes its clinical and microbiome results, marketed probiotic-plus-secretome acne benefits remain unproven. Do not replace standard therapy with an experimental combination.
- Keep using prescribed retinoids, benzoyl peroxide, or other standard care unless your clinician changes it
- Ask sellers which human trial, strain, dose, and lesion outcome supports the exact product
- Treat before-and-after photos, microbiome language, and cell-free wording as marketing, not efficacy data
- Bring the product label to your dermatology visit and ask how it fits your current plan
You Might Also Like
- The 2026 Oral Probiotic and Topical Secretome Acne Trial Protocol: Product-Claim Questions for People With Acne-Prone Skin
- Skin Microbiome Outcomes in the 2026 Probiotic Acne Review: Product-Claim Questions for People With Acne-Prone Skin
- Protective and Acne-Associated Microbial Strains in the 2026 Consensus: Product-Claim Questions for People With Acne-Prone Skin